A major new review published in the high-impact Nature journal Signal Transduction and Targeted Therapy (impact factor >50) is reshaping the conversation around KRAS, one of the most historically “undruggable” oncogenes in human cancer. The article, “ Targeting KRAS mutations: orchestrating cancer evolution and therapeutic challenges ,” led by researchers at the Barbara Ann Karmanos Cancer Institute and Wayne State University, has rapidly gained international attention, becoming one of the most acces...